

Be Elewski

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3101772/be-elewski-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

143
papers

6,929
citations

42
h-index

81
g-index

155
ext. papers

8,053
ext. citations

3.7
avg, IF

5.94
L-index

#	Paper	IF	Citations
143	Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis.. <i>British Journal of Dermatology</i> , 2022 ,	4	
142	Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.. <i>Dermatology and Therapy</i> , 2022 , 12, 911	4	
141	Seborrheic Dermatitis in Older Adults: Pathogenesis and Treatment Options.. <i>Drugs and Aging</i> , 2022 , 1	4.7	0
140	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. <i>British Journal of Dermatology</i> , 2021 , 184, 270-280	4	14
139	Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. <i>British Journal of Dermatology</i> , 2021 , 184, 425-436 ⁴		16
138	Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1140-1142	4.5	4
137	Treatment-resistant tinea corporis, a potential public health issue. <i>British Journal of Dermatology</i> , 2021 , 184, 164-165	4	7
136	Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. <i>JAMA Dermatology</i> , 2021 , 157, 43-51	5.1	12
135	Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. <i>British Journal of Dermatology</i> , 2021 , 184, 450-463	4	61
134	Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. <i>American Journal of Clinical Dermatology</i> , 2021 , 22, 173-192	7.1	21
133	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , 2021 , 184, 1047-1058	4	24
132	Common Cutaneous Infections: Patient Presentation, Clinical Course, and Treatment Options. <i>Medical Clinics of North America</i> , 2021 , 105, 783-797	7	0
131	Treatment-resistant dermatophytosis: A representative case highlighting an emerging public health threat. <i>JAAD Case Reports</i> , 2020 , 6, 1153-1155	1.4	5
130	Honeycomb-like cavities in a single fingernail plate. <i>JAAD Case Reports</i> , 2020 , 6, 89-91	1.4	
129	Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. <i>Journal of Dermatological Treatment</i> , 2020 , 1-5	2.8	13
128	Topical crisaborole is an efficacious steroid-sparing agent for treating mild-to-moderate seborrhoeic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e809-e812 ¹	4.6	
127	Improvement of 11 patients with nail psoriasis with apremilast: Results of an investigator-initiated open-label study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1830-1832	4.5	2

126	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , 2020 , 182, 1348-1358	4	58
125	Rosacea treatment: a patient-centric approach. <i>British Journal of Dermatology</i> , 2020 , 182, 1090-1091	4	1
124	A call for antifungal stewardship. <i>British Journal of Dermatology</i> , 2020 , 183, 798-799	4	1
123	Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 763-768	2.8	4
122	Itch: an under-recognized problem in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1465-1476	4.6	22
121	Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, e431-e432 ²	4.6	2
120	Isolated Nail Dystrophy: An Unlikely Presentation of Metastatic Renal Cell Carcinoma. <i>Skin Appendage Disorders</i> , 2019 , 5, 177-180	1.4	1
119	Successful Treatment of Dermatophytomas in 19 Patients Using Efinaconazole 10% Solution. <i>Skin Appendage Disorders</i> , 2019 , 5, 304-308	1.4	6
118	Lichen Planopilaris in the Setting of Hair Sunscreen Spray. <i>Skin Appendage Disorders</i> , 2019 , 5, 108-110	1.4	2
117	Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 2168-2178	4.6	18
116	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1029-1072	4.5	296
115	Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1305-1313 ^{4.6}	4.6	14
114	Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 90-99.e1	4.5	44
113	Efinaconazole 10% Topical Solution: Case Review of Onychomycosis Patients Who Were Completely Cured at Week 24. <i>Skin Appendage Disorders</i> , 2018 , 4, 67-70	1.4	3
112	Safety of secukinumab in hepatitis B virus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e120-e121	4.6	11
111	Grading Onychomycosis 2018 , 41-45		
110	Subungual Space: The Next Frontier. <i>Skin Appendage Disorders</i> , 2018 , 5, 50-51	1.4	1
109	Single-Center, Prospective, Blinded Study Comparing the Efficacy and Compatibility of Efinaconazole 10% Solution in Treating Onychomycosis with and without Concurrent Nail Polish Use. <i>Skin Appendage Disorders</i> , 2018 , 5, 9-12	1.4	5

108	Ungual Horn. <i>Skin Appendage Disorders</i> , 2018 , 5, 56-59		1.4
107	Fungal (Onychomycosis) and Other Infections Involving the Nail Apparatus 2018 , 349-389		
106	Systemic Treatment of Onychomycosis 2018 , 118-122		
105	Routine and Emerging Techniques in Onychomycosis Diagnosis 2018 , 47-59		
104	Image Gallery: Molluscum contagiosum-like facial lesions in a patient with a renal transplant: deep dermatophytosis due to <i>Trichophyton rubrum</i> . <i>British Journal of Dermatology</i> , 2018 , 178, e328	4	4
103	Cutaneous plasmacytosis resembling pityriasis rosea in a 66-year-old white woman: A rare disease presenting in an unusual patient demographic. <i>JAAD Case Reports</i> , 2017 , 3, 78-81	1.4	1
102	Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 79-87.e1	4.5	47
101	Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017 , 2, 73-80	1.1	1
100	AB0756 Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis 2017 ,		2
99	Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review. <i>Dermatology and Therapy</i> , 2016 , 6, 555-578	4	22
98	Confirmatory Testing for Onychomycosis. <i>JAMA Dermatology</i> , 2016 , 152, 848	5.1	3
97	Response to "A financial perspective on the topical treatment of onychomycosis". <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, e39	4.5	
96	Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. <i>American Journal of Clinical Dermatology</i> , 2016 , 17, 33-47	7.1	38
95	Secukinumab (AIN-457) for the treatment of Psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 187-202	3.8	6
94	Successful Treatment of <i>Paecilomyces lilacinus</i> Onychomycosis with Efinaconazole and Tavaborole. <i>Skin Appendage Disorders</i> , 2016 , 1, 169-71	1.4	9
93	Topical Treatment for Onychomycosis: Is it More Effective than the Clinical Data Suggests?. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016 , 9, 34-39	1.2	39
92	Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. <i>International Journal of Dermatology</i> , 2016 , 55, 401-7	1.7	27
91	Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. <i>International Journal of Dermatology</i> , 2016 , 55, e147-55	1.7	13

90	Onychomycosis: Practical Approaches to Minimize Relapse and Recurrence. <i>Skin Appendage Disorders</i> , 2016 , 2, 83-87	1.4	29
89	An Idiopathic Leukonychia Totalis and Leukonychia Partialis Case Report and Review of the Literature. <i>Skin Appendage Disorders</i> , 2015 , 1, 38-42	1.4	15
88	Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 62-9	4.5	109
87	Tanning accelerators: prevalence, predictors of use, and adverse effects. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 99-104	4.5	2
86	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. <i>British Journal of Dermatology</i> , 2015 , 173, 949-61	4.1	196
85	Eccrine Poromatosis: Case Report, Review of the Literature, and Treatment. <i>Skin Appendage Disorders</i> , 2015 , 1, 95-8	1.4	4
84	The ABCDEF Rule: Combining the "ABCDE Rule" and the "Ugly Duckling Sign" in an Effort to Improve Patient Self-Screening Examinations. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015 , 8, 15	1.2	16
83	Risk Factors and Comorbidities for Onychomycosis: Implications for Treatment with Topical Therapy. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015 , 8, 38-42	1.2	60
82	A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. <i>Cutis</i> , 2015 , 96, 54-61	0.4	14
81	Secukinumab in plaque psoriasis--results of two phase 3 trials. <i>New England Journal of Medicine</i> , 2014 , 371, 326-38	59.2	1319
80	Tavaborole for the treatment of onychomycosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1439-48	4	33
79	Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 227-31	4.6	51
78	Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. <i>Journal of the American Academy of Dermatology</i> , 2013 , 68, 600-608	4.5	170
77	Item-level psychometric properties for a new patient-reported psoriasis symptom diary. <i>Value in Health</i> , 2013 , 16, 1014-22	3.3	21
76	Efinaconazole 10% solution: a new topical antifungal therapy for onychomycosis. <i>Expert Review of Dermatology</i> , 2013 , 8, 347-356		2
75	Current and emerging options in the treatment of onychomycosis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2013 , 32, S9-12	1.4	25
74	Onychomycosis: an overview. <i>Journal of Drugs in Dermatology</i> , 2013 , 12, s96-103	2.2	21
73	Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 188-200	4.6	142

72	Tinea Capitis: Fluconazole in Trichophyton tonsurans Infection. <i>Pediatric Dermatology</i> , 2009 , 15, 229-232	1.9	
71	Onychomycosis and diabetes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23, 1119-22	4.6	37
70	An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. <i>Clinics in Dermatology</i> , 2009 , 27, S48-53	3	18
69	Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2008 , 59, 41-54	4.5	95
68	Advances in topical and systemic antifungals. <i>Dermatologic Clinics</i> , 2007 , 25, 165-83, vi	4.2	50
67	Percutaneous absorption kinetics of topical metronidazole formulations in vitro in the human cadaver skin model. <i>Advances in Therapy</i> , 2007 , 24, 239-46	4.1	14
66	Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 439.e1-10	4.5	69
65	Onychomycosis: diagnosis and definition of cure. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 939-44	4.5	139
64	Azelaic acid 15% gel for treatment of rosacea. <i>Expert Review of Dermatology</i> , 2006 , 1, 535-545		1
63	Modification of the Nail Psoriasis Severity Index. <i>Journal of the American Academy of Dermatology</i> , 2005 , 53, 745-6; author reply 746-7	4.5	49
62	Clinical diagnosis of common scalp disorders. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2005 , 10, 190-3	1.1	36
61	Onychomycosis 2005 , 123-131		2
60	Improvement in nail psoriasis with alefacept. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, P145	4.5	3
59	Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 748-52	4.5	168
58	The use of 40% urea cream in the treatment of moccasin tinea pedis. <i>Cutis</i> , 2004 , 73, 355-7	0.4	16
57	A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. <i>Archives of Dermatology</i> , 2003 , 139, 1444-50		98
56	Tinea capitis in adult women masquerading as bacterial pyoderma. <i>Journal of the American Academy of Dermatology</i> , 2003 , 49, S177-9	4.5	26
55	Tinea corporis, tinea cruris, tinea nigra, and piedra. <i>Dermatologic Clinics</i> , 2003 , 21, 395-400, v	4.2	86

54	Office practice-based confirmation of onychomycosis: a US nationwide prospective survey. <i>Archives of Internal Medicine</i> , 2002 , 162, 2133-8		21
53	Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine. <i>Journal of the American Academy of Dermatology</i> , 2002 , 46, 371-5	4.5	19
52	Cutaneous fungal infections in the elderly. <i>Clinics in Geriatric Medicine</i> , 2002 , 18, 59-75	3.8	23
51	Antifungal drug interactions. Avoidance requires more than memorization. <i>Postgraduate Medicine</i> , 2000 , 107, 41-3	3.7	11
50	The diagnosis of nail fungus infection revisited. <i>Archives of Dermatology</i> , 2000 , 136, 1162-4		26
49	A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. <i>Journal of the American Academy of Dermatology</i> , 2000 , 43, 641-8	4.5	354
48	New developments in cutaneous fungal infections. <i>Current Problems in Dermatology</i> , 2000 , 12, 81-85		3
47	Onychomycosis. Treatment, quality of life, and economic issues. <i>American Journal of Clinical Dermatology</i> , 2000 , 1, 19-26	7.1	87
46	Asthma induced by allergy to <i>Trichophyton rubrum</i> . <i>Journal of the European Academy of Dermatology and Venereology</i> , 1999 , 12, 250-253	4.6	8
45	Novel treatment strategies for superficial mycoses: introduction. <i>Journal of the American Academy of Dermatology</i> , 1999 , 40, S1-2	4.5	5
44	Treatment of tinea capitis: beyond griseofulvin. <i>Journal of the American Academy of Dermatology</i> , 1999 , 40, S27-30	4.5	38
43	Asthma induced by allergy to <i>Trichophyton rubrum</i> 1999 , 12, 250		1
42	Once-weekly fluconazole in the treatment of onychomycosis: introduction. <i>Journal of the American Academy of Dermatology</i> , 1998 , 38, S73-6	4.5	16
41	Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. <i>Journal of the American Academy of Dermatology</i> , 1998 , 38, S77-86	4.5	115
40	Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. <i>Journal of the American Academy of Dermatology</i> , 1998 , 38, S87-94	4.5	32
39	Treatment of tinea capitis: Should terbinafine replace griseofulvin?. <i>Journal of Dermatological Treatment</i> , 1998 , 9, S9-S11	2.8	5
38	Onychomycosis: pathogenesis, diagnosis, and management. <i>Clinical Microbiology Reviews</i> , 1998 , 11, 415-34		378
37	Tinea capitis: fluconazole in <i>Trichophyton tonsurans</i> infection. <i>Pediatric Dermatology</i> , 1998 , 15, 229-32	1.9	19

36	Prevalence of Onychomycosis in Patients Attending a Dermatology Clinic in Northeastern Ohio for Other Conditions. <i>Archives of Dermatology</i> , 1997 , 133, 1172		136
35	Superficial fungal infections. Errors to avoid in diagnosis and treatment. <i>Postgraduate Medicine</i> , 1997 , 101, 279-87	3.7	11
34	Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. <i>Journal of the American Academy of Dermatology</i> , 1997 , 37, 740-5	4.5	96
33	One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial. <i>Journal of the American Academy of Dermatology</i> , 1997 , 36, S15-9	4.5	28
32	Onychomycosis in children: prevalence and treatment strategies. <i>Journal of the American Academy of Dermatology</i> , 1997 , 36, 395-402	4.5	146
31	The effect of toenail onychomycosis on patient quality of life. <i>International Journal of Dermatology</i> , 1997 , 36, 754-6	1.7	69
30	Treatment of tinea capitis with itraconazole. <i>International Journal of Dermatology</i> , 1997 , 36, 539-41	1.7	1
29	A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. <i>British Journal of Dermatology</i> , 1997 , 136, 786-789	4	88
28	Tinea capitis. <i>Dermatologic Clinics</i> , 1996 , 14, 23-31	4.2	32
27	International summit on cutaneous antifungal therapy, focus on tinea capitis, Boston, Massachusetts, November 11-13, 1994. <i>Pediatric Dermatology</i> , 1996 , 13, 69-77	1.9	10
26	Surgical pearl: nail micronizer. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 278	4.5	3
25	Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 282-6	4.5	111
24	Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 287-9	4.5	34
23	Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. Guidelines/Outcomes Committee. American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 290-4	4.5	27
22	Diagnostic techniques for confirming onychomycosis. <i>Journal of the American Academy of Dermatology</i> , 1996 , 35, S6-9	4.5	61
21	Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. <i>Journal of the American Academy of Dermatology</i> , 1996 , 35, 216-9	4.5	41
20	Clinical pearl: diagnostic procedures for tinea capitis. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 498-9	4.5	3
19	Onychomycosis caused by <i>Scytalidium dimidiatum</i> . <i>Journal of the American Academy of Dermatology</i> , 1996 , 35, 336-8	4.5	56

18	A U.S. epidemiologic survey of superficial fungal diseases. <i>Journal of the American Academy of Dermatology</i> , 1996 , 35, 539-42	4.5	151
17	Guidelines of care for superficial mycotic infections of the skin: mucocutaneous candidiasis. Guidelines/Outcome Committee. American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 110-5	4.5	17
16	Guidelines of care for superficial mycotic infections of the skin: onychomycosis. Guidelines/Outcomes Committee. American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 116-21	4.5	45
15	Guidelines of care for superficial mycotic infections of the skin: Piedra. Guidelines/Outcomes Committee. American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 122-4	4.5	20
14	Cutaneous mycoses in children. <i>British Journal of Dermatology</i> , 1996 , 134 Suppl 46, 7-11: discussion 37-84		43
13	Clinical pearl: diagnosis of onychomycosis. <i>Journal of the American Academy of Dermatology</i> , 1995 , 32, 500-1	4.5	29
12	Thrombocytopenia caused by fluconazole therapy. <i>Journal of the American Academy of Dermatology</i> , 1995 , 32, 525-6	4.5	10
11	Clinical pearl: systemic antifungal drugs and drug interactions. <i>Journal of the American Academy of Dermatology</i> , 1995 , 33, 259-60	4.5	26
10	Failure of clotrimazole-betamethasone dipropionate cream in treatment of <i>Microsporum canis</i> infections. <i>Journal of the American Academy of Dermatology</i> , 1995 , 32, 1050-1	4.5	8
9	Cutaneous involvement with <i>Cryptococcus neoformans</i> in AIDS. <i>Journal of the American Academy of Dermatology</i> , 1994 , 30, 844-8	4.5	42
8	Tinea capitis: itraconazole in <i>Trichophyton tonsurans</i> infection. <i>Journal of the American Academy of Dermatology</i> , 1994 , 31, 65-7	4.5	45
7	Clinical pearl: proximal white subungual onychomycosis in AIDS. <i>Journal of the American Academy of Dermatology</i> , 1993 , 29, 631-2	4.5	52
6	Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1- and 4-week treatment regimens. <i>Journal of the American Academy of Dermatology</i> , 1993 , 28, 648-51	4.5	65
5	Mechanisms of action of systemic antifungal agents. <i>Journal of the American Academy of Dermatology</i> , 1993 , 28, S28-S34	4.5	91
4	<i>Hendersonula toruloidea</i> and <i>Scytalidium hyalinum</i> . <i>Archives of Dermatology</i> , 1991 , 127, 1041		34
3	The superficial mycoses and the dermatophytes. <i>Journal of the American Academy of Dermatology</i> , 1989 , 21, 655-73	4.5	44
2	Eruptive lesions and malignancy. <i>International Journal of Dermatology</i> , 1985 , 24, 617-29	1.7	3
1	In vivo suppression of neutrophil chemotaxis by systemically and topically administered tetracycline. <i>Journal of the American Academy of Dermatology</i> , 1983 , 8, 807-12	4.5	53

